VISION STATEMENT 
A world without vaccine preventable disease, disability, and death. 
MISSION STATEMENT
To protect the health of Americans and global citizens by preventing disease, disability, and death through immunization. 
BACKGROUND
& INTRODUCTION
Childhood immunization is one of the most cost-effective of all health interventions.  In the past two decades, immunization has prevented an estimated 20 million deaths globally from vaccine-preventable diseases.  

The United States has greatly reduced its burden of vaccine-preventable diseases (VPDs) through childhood immunization.  However, U.S. children and adults remain at risk for VPDs largely due to their widespread occurrence in other countries. Globally, more than 2 million childhood deaths from VPDs are prevented each year (2004 estimate), and an additional 600,000 hepatitis B-related deaths from liver cirrhosis and hepatoma that may otherwise have occurred in adulthood are prevented.    

Each year, more than 130 million children are born worldwide who need immunization services.  While 78% of the world’s infants receive diphtheria-tetanus-pertussis vaccine (DTP3) – the benchmark indicator of annual routine immunization coverage – an estimated 27 million infants remain unvaccinated.   One in six children is not vaccinated against tuberculosis; 1 in 4 is not vaccinated against measles, only half of the world’s infants are fully immunized against hepatitis B, and 3 in 4 are not vaccinated against Haemophilus influenzae type B (Hib) disease. 

The negative impact of these gaps in immunization is enormous.  An estimated 1.4 million children under age five died from the six major VPDs in 2004, with a further 1.1 million deaths from pneumococcal disease and rotavirus (for which vaccines are available in the United States but rarely used in developing countries).  

Since 1991, CDC has provided substantial financial and technical support for polio eradication and measles elimination.  CDC’s yearly investment in global immunization has grown from $3.1 million to $140 million in 2006.  In addition, CDC currently has 28 staff seconded to international health organizations, such as WHO, UNICEF, Pan American Health Organization, World Bank, and the American Red Cross, providing full-time technical and operational support to priority countries and regions.  
In keeping with this growth, CDC has a much broader role and greater influence in the field of global immunization than it did even five years ago.  In addition to being a key partner in both the Global Polio Eradication Initiative and the Measles Initiative, CDC has played a critical role, along with WHO and UNICEF, in developing the Global Immunization Vision and Strategy for 2006-2015 (GIVS); has a representative on the Global Alliance for Vaccines and Immunization (GAVI) Working Group; is an implementing partner in the Hib Initiative, charged by the GAVI Alliance to assist countries to make evidence-based decisions regarding the introduction of Hib vaccine into national programs; and is supporting pilot projects in three countries to strengthen the delivery of routine immunization.   

Since CDC’s last five-year strategic plan for global immunization (2002-2006), much has changed.  There has been a renewed commitment from global partners for preventing VPDs among the world’s children.  This includes $4 billion from the International Finance Facility for Immunization (IFFIm) over the next 10 years and a $750 million investment from the Bill and Melinda Gates Foundation for 2006-2015.  Both of these investments will support the GAVI Fund for several initiatives including supporting measles SIAs, strengthening immunization and health systems, eliminating maternal and neonatal tetanus, establishing the polio vaccine stockpile, improving access to underused vaccines, and speeding the development and introduction of new vaccines in GAVI-eligible countries.   Investment cases for introduction of rotavirus vaccine and pneumococcal conjugate vaccine have recently been approved by the GAVI Board. 

The GAVI Fund will finance two major strategic approaches to reducing the number of deaths among children under five in more than 70 of the world’s poorest countries.  These funds will be used to invest in the introduction of new and underused vaccines including combination vaccines for diphtheria, tetanus, pertussis, hepatitis B and Hib.  It is expected that additional vaccines (pneumococcal conjugate, rotavirus, meningococcal conjugate, Japanese encephalitis and human papillomavirus [HPV]) could be supported within the next five years.  Money will also be targeted towards strengthening of immunization delivery systems, including support for increasing routine immunization coverage in the poorest countries and for conducting mass immunization campaigns to rapidly reduce mortality from measles and tetanus.  It is estimated that this investment will save the lives of five million children under five by 2015, and a further five million adult lives after 2015.

To protect children in the United States and reduce the global burden of VPDs, the Centers for Disease Control and Prevention (CDC) supports a broad range of programmatic and research efforts.  CDC’s experience working with domestic immunization partners provides valuable lessons and linkage with our international efforts and priorities. Tremendous progress has been achieved through these efforts:

Polio: The number of global polio cases has been reduced by more than 99.5% since 1988, including the prevention of five million cases of paralysis and more than 250,000 deaths.  In 2007, only four countries remain endemic for polio, the fewest ever.

Measles and Rubella:  Endemic measles has been eliminated from the Western Hemisphere and no importations from Latin America have occurred in the United States since 2000 (in 1990, more than 90% of measles importations into the U.S. were from Latin America); building on this achievement, CDC is working to control measles in those parts of the world responsible for importations into the United States.  CDC is a founding member of the Measles Initiative, which, together with host governments, has helped cut measles deaths by 75% in Africa from 1999-2005.  Global measles deaths have dropped by 60%, falling from 873,000 deaths in 1999 to 345,000 in 2005.  Supplemental vaccination campaigns and improved routine immunization between 1999 and 2005 prevented 2.3 million measles deaths.  CDC is also a major partner in regional initiatives in PAHO and the European Region of WHO to eliminate rubella and congenital rubella syndrome (CRS) by 2010.  In addition, CDC provides technical support to other regions and countries in the context of the increasing use of rubella-containing vaccine from 65 countries in 1996 to 116 countries in 2004. 

Other VPDs: With technical support from WHO, UNICEF, CDC and other partners, global immunization coverage for DTP3 has increased from 20% in 1980 to 78% in 2005.  Hepatitis B vaccine is now given routinely in 154 countries.  However, approximately 40,000 immigrants with chronic hepatitis B are admitted each year to the United States.  Increasing the number of countries offering the vaccine routinely will reduce the burden of hepatitis B (HBV) infections in this country.  CDC support has greatly increased for enhancing global influenza surveillance and promoting wider use of seasonal influenza vaccine both to reduce the burden of influenza disease and to build capacity for pandemic influenza preparedness and response.  Hib vaccine is currently provided routinely in 114 countries. 
An opportunity now exists to expand support for the introduction of rotavirus, HPV, and pneumococcal conjugate vaccine to further reduce illness and death in other countries and protect the health of children and adults in the United States. 

Linkages with non-vaccine child survival interventions: Immunization campaigns are increasingly used as a platform for delivering additional child survival interventions.  Through 2006, nearly 31 million doses of de-worming medicine and more than 18 million insecticide-treated bed nets have been provided during immunization campaigns in Africa.  The bed nets already have prevented tens of thousands of childhood deaths from malaria. In addition, an estimated 1.25 million childhood deaths have been averted by administration of Vitamin A during polio immunization campaigns since 1998.

CDC also actively supports the evaluation and introduction of new vaccines to prevent pneumonia, meningitis, and diarrheal illness in children, and research to develop new vaccines to protect against the greatest killers in developing countries: HIV, tuberculosis, and malaria.  In addition, CDC provides support to strengthen routine immunization programs and to increase the safety of vaccines and injections.

This is a critical moment for CDC to remain deeply engaged in global immunization.  To fully realize the benefits of the increased interest and support for global immunization, there is an urgent need to provide expertise in immunization program implementation, epidemiologic and laboratory surveillance of VPDs, technical and operational support to strengthen immunization programs, and technical support for development, introduction and evaluation of new vaccines.  Moreover, CDC can leverage its technical and programmatic support and funding to positively influence the support of other global health partners for global immunization.  CDC shares the established goals of protecting U.S. citizens from VPDs and reducing the burden of VPDs in all countries, and it has substantial technical expertise to support all aspects of global immunization.  

Support for global immunization requires close partnership with other international agencies and donors engaged in global immunization,
including WHO, UNICEF, World Bank, Rotary International, American Red
Cross, International Federation of Red Cross and Red Crescent Societies,
the UN Foundation, the Bill and Melinda Gates Foundation, and the GAVI
Alliance.  CDC will continue to support and expand these partnerships to
assure the greatest impact of CDC’s technical and scientific resources on reducing the burden of VPDs.

The most immediate global immunization challenges include:

•		Controlling, eliminating, and/or eradicating VPDs.  This challenge
	includes the goals of certifying global polio eradication by 2011
	and reducing annual measles deaths by 90% by 2010 (compared with
	2000 figures).  Progress in global immunization will contribute
	substantially to achievement of Millennium Development Goal #4:  			“Reducing child mortality by two-thirds
	between 1990 and 2015.”
•	Improving global surveillance for VPDs and immunization
	program monitoring. 
•	Strengthening and sustaining effective immunization services
	and linking immunization delivery with other priority health
	interventions.
•	Developing and supporting the introduction of new vaccines to
	prevent diseases of global health importance, including vaccines
	targeting pneumococcal and epidemic meningococcal disease,
	rotavirus, Japanese encephalitis, influenza and avian flu, malaria,
	HIV, HPV, and TB.
•	Building and sustaining partnerships and collaborations to
	support and promote the availability and use of vaccines needed
	in developing countries.

At the same time, these challenges must be addressed in the context of broader health systems challenges, which include:

•	the need to support immunization in the face of multiple
	competing health priorities at the national level;
•	the need to determine and document the impact of immunization
	on MDGs and the primary causes of mortality and morbidity;
•	overall deficiencies in health systems, particularly health
	management;
•	the financial sustainability of immunization programs, especially for 		new vaccines; and 
•	the introduction of new vaccines while maintaining and increasing 			coverage for current routine EPI.

The purpose of this strategic plan is to articulate the goals, objectives, and strategies of CDC and its global partners for effectively meeting these global immunization challenges from 2006-2010.  Achievement of these goals will require that CDC work closely and effectively with global partners.  This document is intended to build on and complement CDC’s previous five-year plan, Global Immunization 2002-2006: An Over-Arching Strategy for CDC.   

Summary of Goals

Working with global partners, CDC will pursue the following major global immunization goals:

Goal 1:		Control, eliminate, and/or eradicate vaccine-preventable
					disease, disability, and death globally.

Goal 2:		Improve global surveillance for VPDs (integrated
					epidemiologic and laboratory surveillance) and health
					information systems for immunization program monitoring,
					and consolidate these structures and functions into
					a Global Framework for Immunization Monitoring and
					Vaccine Preventable Disease Surveillance that can support
					the immunization delivery system.

Goal 3: 		Build and sustain safe and effective immunization services
					as a component of health delivery systems, and promote
					opportunities for linking immunization delivery with other 									priority health interventions.

Goal 4:		Support introduction of new vaccines to prevent diseases of
					global public health importance, by assisting in vaccine
					development, evaluating vaccine safety and efficacy, and
					assisting countries both in making evidence-based decisions 
					and in implementation issues.

Goal 5:		Build and strengthen multilateral and bilateral partnerships 								and other collaborative efforts to support availability, equitable
					access, sustainable financing, and use of vaccines for all children 						and adults globally, especially in developing countries.
GOALS, OBJECTIVES, AND STRATEGIES
GOAL 1
Control, eliminate, and/or eradicate vaccine-preventable disease, disability, and death globally.
Objectives:
1.		End global transmission of polio by 2008, certify global polio 									eradication by 2011, and initiate global action plan for poliovirus
		containment and oral polio vaccine (OPV) cessation (Global Action Plan
		for Laboratory	Containment of Polioviruses, 3rd edition [GAP III]).

2.		By 2010, reduce by 90% the annual global measles-related mortality
		compared with the 2000 estimates (2000 baseline: 734,000 deaths).
		(GIVS)
		2. a. Eliminate measles in EURO by 2010, EMRO by 2010, and WPRO by 					 2012. Sustain measles elimination in PAHO (target achieved in 2002). 					(WHO Regional Goals)
		2. b. By 2010, at least 75% of countries (144 of 192) will have achieved 					>90% first dose measles coverage.  (WHO Strategic Plan 2006-9)
		2. c. By 2010, 100% of countries will have implemented a second
		opportunity for measles immunization within the preceding 5 years
		through routine or supplemental immunization activities.  (WHO 							Strategic Plan 2006-9)

3.		Eliminate rubella and congenital rubella syndrome (CRS) in the
		American and European Regions of WHO by 2010 and support
		the control and prevention of rubella and CRS worldwide. 

4.		By 2010, all countries will have introduced hepatitis B vaccine in
		infant immunization schedules.  (WHO Strategic Plan 2006-9) 
		4. a. EMRO target:  reduce seroprevalence of HBsAg to less than 1% in
		age cohorts born since introduction of routine vaccination.
		4. b. WPRO target:  By 2012, reduce the seroprevalence of HBsAg to less 				than 2% in 5-year-old children born since introduction of routine 							vaccination (and achieve 80% coverage with birth dose within 
		24 hours of birth). 

5.		Eliminate neonatal tetanus (NNT) (<1 case per 1000 live births) in all
		districts of all countries by 2010.
Strategies:
•		Provide technical and financial support to countries and partners for 				surveillance and vaccination campaigns. 

•		Provide technical and financial support to partners and countries
		to develop, implement and evaluate disease reduction and
		elimination strategies. 

•		Promote the development of case-based surveillance for VPDs, with 				expansion of laboratory networks for viral and bacterial diseases. (also 			for Goal 2)

•		Ensure that all countries have access to a WHO-accredited laboratory 				that provides accurate virologic and bacteriologic data.  (also for Goal 2)

•		Complete the research agenda to establish the scientific basis for 						stopping use of OPV, modifying vaccination strategies to achieve 						eradication, and implementing safeguards to minimize risks in the post-			eradication period. 

•		Promote wider use of seasonal influenza vaccine both to reduce
		the burden of influenza disease and to build capacity for pandemic
		influenza preparedness and response.
GOAL 2
Improve global surveillance for VPDs (integrated epidemiologic and laboratory surveillance) and health information systems for immunization program monitoring, and consolidate these structures and functions into a Global Framework for Immunization Monitoring and Vaccine Preventable Disease Surveillance that can support the immunization delivery system.
Objectives: 
1.		By end of 2007, in collaboration with WHO, develop
		implementation strategy for the “Global Framework for
		Immunization Program Monitoring and Vaccine Preventable
		Disease Surveillance, 2006-2010”, which outlines a strategic
		approach for strengthening VPD surveillance, laboratory network
		capacity, immunization coverage monitoring, and monitoring of
		other key immunization program performance measures.    

2.		By 2010, ensure that 100% of countries have access to
		proficient, accredited laboratories for diagnosis and confirmation
		of polio, measles/rubella, influenza, hepatitis B, yellow fever (as
		epidemiologically appropriate), pertussis, and diphtheria. 

3.		Expand regional and national surveillance of diseases that can
		be prevented by new vaccines and strengthen laboratory										capacity to monitor the impact of these new vaccines on disease
		patterns and program operations, to provide baseline data to
		inform decisions on new vaccine introduction and monitor
		impact.

4.		By 2010, ensure that 90% of national immunization programs will
		have effective surveillance systems and technical support to
		monitor immunization safety.  

5.		By 2007, build and maintain an effective VPD surveillance system
		with strong linkages to broader networks designed for epidemic
		preparedness and response, such as the Global Disease
		Detection Network (GDD) and Global Alert and Response
		Network (GOARN), as well as the global influenza lab network,
		enabling the appropriate and timely use of vaccines and
		other control strategies in the context of emerging or 
		threatening epidemics.
Strategies:  	
•		Maintain certification quality surveillance for acute flaccid 
		paralysis (AFP).

•		Expand existing surveillance systems (including polio and measles 
		surveillance) to progress towards effective case-based surveillance
		for VPDs, both for existing vaccines and those recently or about to be
		introduced.   (GIVS)

•		Expand existing laboratory networks, including the polio and measles
		laboratory networks, and other regional and local networks such as the
		Pediatric Bacterial Meningitis Network and sentinel surveillance								networks for pneumococcal and rotavirus vaccines, to include other
		priority diseases such as influenza and avian flu, pertussis, diphtheria, 					meningococcal disease, Japanese encephalitis, and HPV. (GIVS)

•		Strengthen laboratory capacity to establish baseline disease burden
		and  monitor the impact of new vaccines on disease patterns (also for
		Goal 4). (GIVS)

•		Strengthen national and regional public health laboratories in
		developing countries by providing the training, equipment, reagents,
		and quality control procedures needed to sustain high quality
		diagnostics for all VPDs and other priority diseases.  (GIVS)

•		At the global level, develop new diagnostic tests, tools and procedures
		to improve both field-based and laboratory confirmation of diagnoses
		(in partnership with WHO).  (GIVS)

•		Strengthen local capacity for data management and analysis for
		decision-making and outbreak detection.  (GIVS)

•		Improve coverage monitoring of vaccines and other linked health
		interventions and the use of information at district and local levels
		through strengthening human resource capacity, monitoring of the
		quality of data, and improved tools for data compilation, feedback and
		supervision.  (GIVS)

•		Contribute to the development and introduction of better tools
		(e.g., computer software) for monitoring coverage of vaccines and
		linked interventions, vaccine and logistics management, and disease
		surveillance to better support data entry, analysis, feedback, and
		utilization, and to improve program performance and management.
•		Establish surveillance and response systems for adverse events
		following immunization, both for existing vaccines and for new
		vaccines as they are introduced into national schedules.

•		For seasonal and avian influenza:
			º	Provide technical and financial support to countries to establish
				effective surveillance for influenza to determine burden of disease
				and to understand the epidemiology of influenza virus circulation
				in the developing world and the tropics.
			º	Provide technical and financial support to countries to establish
				early warning systems for human and avian influenza outbreaks.
			º	Train rapid response teams to respond to surveillance data with
				timely investigation and containment.
			º	Promote community involvement in outbreak reporting.
			º	Encourage countries to establish coordination mechanisms
				between ministries of health and agriculture to improve their
				ability to detect and respond to human influenza outbreaks
				associated with zoonotic transmission.
			º	Enhance laboratory capacity for rapid diagnosis of influenza.

•		Assess and evaluate the usefulness of current systems for monitoring
		VPDs (e.g., Pediatric Bacterial Meningitis Surveillance, Integrated
		Disease Surveillance and Response [IDSR] in Africa) and impact of
		vaccine introduction. 

•		Develop innovative/alternative approaches to conducting case-based
		sentinel surveillance 

•		Improve communication, coordination, and (as needed) sharing of
		surveillance data at country level between the immunization program
		and communicable disease group within Ministries of Health.   
GOAL 3
Build and sustain safe and effective immunization services as a component of health delivery systems, and promote opportunities for linking immunization delivery with other priority health interventions.  
Objectives:
1.		By 2010, countries will reach at least 90% national vaccination coverage
		and at least 80% vaccination coverage in every district or equivalent
		administrative unit.  (GIVS)

2.		By 2010, vaccines are given consistent with safe injection practices in all
		countries, and at least 65% of developing countries will be using only
		auto-disable syringes or needle-free devices for immunizations.  (WHO
		Strategic Plan 2006-9)

3.		By 2010, at least 5 non-vaccine interventions (e.g., vitamin A, other
		micronutrients, insecticide-treated bed net distribution, de-worming
		treatments, integrated management of childhood illnesses [IMCI])
		will be integrated with EPI for which consensus guidelines are available
		at the regional level for national program management. (WHO Strategic
		Plan 2006-9)  

4.		By 2010, at least 4 vaccines will have a global recommendation for
		routine immunization beyond infancy, including new vaccines or new
		indications for existing vaccines.  (WHO Strategic Plan 2006-9)

Strategies:
•		Provide support to countries and partners to strengthen key 								components of VPD program management and delivery, including the 			formulation and implementation of comprehensive multi-year national 			plans of action.

•		Provide support to countries and partners for monitoring and 							evaluation of VPD programs.

•		Promote regular immunization program monitoring at local, district,
		and national levels and provide feedback on performance, 									impediments,and new opportunities to all partners.  (GIVS)

•		Where appropriate, perform operations research and evaluation of 					“what works” to improve the delivery of immunization, to make systems
		more effective, efficient and equitable, and to improve immunization 				coverage.  (GIVS)

•		Expand vaccination beyond the traditional infant target age groups
		(to include older children, adolescents and adults) by defining target
		populations and age groups for vaccination appropriate to the national
		situation, and supporting introduction of school immunization laws.
		(GIVS)

•		Use a combination of approaches to reach everyone targeted for
		immunization, including the Reaching Every District (RED) strategy, and
		evaluate implementation of the RED strategy.

•		Assess health and economic impacts of vaccination programs by
		applying standard tools to assess the cost-effectiveness of different
		immunization schedules and strategies in a range of demographic,
		geographic, and epidemiological settings. (GIVS)
•		Provide technical support to countries to introduce, sustain, and
		monitor recommended safe injection practices for all vaccinations,
		including the use of auto-disable syringes or needle-free devices.

•		Assist countries in analyzing the economics of their immunization
		program and securing the necessary funding for sustainable
		achievement of the program objectives.

•		Support programs to incorporate vitamin A, insecticide-treated bed
		nets, de-worming medicine, health education, and other appropriate
		health interventions into routine childhood immunization programs.

•		With partners, develop standardized methods for monitoring
		and evaluating the efficiency, effectiveness and impact of combined
		interventions to improve coverage, and adapt them for use at the
		district and service delivery level. (GIVS) 

•		Partner with UNICEF, WHO, and GAVI to address vaccine procurement
		and supply as a global issue, in keeping with CDC’s role as a vaccine
		funding agency.

•		Assist in the interpretation of surveillance, disease burden data, and
		planning information for policy development at national, regional, 
		and global levels.  
GOAL 4 
Support introduction of new vaccines to prevent diseases of global public health importance, by assisting in vaccine development, evaluating vaccine safety and efficacy, and assisting countries both in making evidence-based decisions and in implementation issues.

Objectives
1.		Working with WHO, ensure that within 5 years of introduction of a new
		vaccine into the routine immunization program of each country,
		coverage reaches the same level as that for other vaccines given at the
		same age.  (GIVS)

2.		Working with WHO, complete development by 2010 of the evidence
		base, including burden of disease, to assess the appropriateness of
		introduction into immunization programs of 5 new vaccines (human
		papillomavirus [HPV], Japanese encephalitis, meningococcal A 								conjugate, pneumococcal conjugate, rotavirus). 
		(WHO Strategic Plan 2006-9)

3.		Working with WHO, establish a network by 2010 of at least 10
		sentinel countries with a monitoring system for adverse events 								following immunization (AEFIs) and post-marketing surveillance
		of new vaccines.  (WHO Strategic Plan 2006-9)

4.		Introduce Haemophilus influenzae type b (Hib) vaccine in all countries
		by 2010, except those in which robust epidemiological evidence exists
		of low disease burden, lack of benefit or overwhelming impediments to
		implementation (GAVI, SAGE 2005).   

5.		By 2010, work with WHO to ensure that all nerve tissue-based vaccines
		for human rabies prevention are replaced by safer, more effective, and
		equally affordable tissue culture products.
Strategies:
•		Collaborate with WHO and other partners on development of new 					vaccines and advocacy for their affordable and equitable introduction.

•		Strengthen country capacity to ensure effective and sustainable
		introduction of new vaccines and technologies based on informed
		decisions.

•		Establish surveillance and response systems for adverse events
		following immunization for new vaccines as they are introduced into
		national schedules.

•		Strengthen country capacity to assess disease burden and the cost
		and cost-effectiveness of new or underutilized vaccines and
		technologies through the use of standard tools.  (GIVS)

•		Ensure effective and sustainable introduction of new vaccines and
		technologies.  (GIVS) 

•		Integrate the introduction of each new vaccine into each country’s
		multi-year national plan of action, including a financial analysis.  (GIVS)

•		Generate geographically and epidemiologically representative clinical
		data on vaccine effectiveness and conduct post-licensure evaluations of
		the impact of vaccination on disease patterns and child survival.   (GIVS) 

•		Promote research and development of new vaccines against diseases of 			public health importance.  (GIVS)

•		Work with partners to expedite evaluation of the efficacy of new 						rotavirus vaccines in settings in Asia and Africa where most rotavirus 				mortality occurs. 

•		Encourage countries to strengthen influenza surveillance and
		vaccination policy development to determine the burden of influenza,
		the cost-effectiveness of introducing influenza vaccine and its impact,
		and to decide on the optimal vaccination strategy to use.  
GOAL 5 
Build and strengthen multilateral and bilateral partnerships and other collaborative efforts to support availability, equitable access, sustainable financing, and use of vaccines for all children and adults globally, especially in developing countries.
Objectives:
1.		Engage in new and strengthen existing partnerships to help achieve
		our mission (e.g., the new measles-malaria partnership), both at the
		global level as well as regional VPD partnerships tailored to the specific
		needs and partner composition of regions.

2.		Enhance capacity of CDC and domestic and international partners to
		support global immunization programs.

3.		Coordinate CDC’s vaccine funding through UNICEF and PAHO Revolving
		Fund, and with vaccine manufacturers.
Strategies:
•		Participate in establishing global immunization priorities, goals and
		objectives, including engagement with the GAVI Alliance
		(with partners).

•		Collaborate with partners in communicating the value of vaccines, and
		in the dissemination of accurate information about the benefits and
		risks of vaccines and immunization.

•		Participate in interagency coordinating committees (ICCs) at the
		regional level and in selected priority countries.

•		Work with global partners to secure and maintain the combined
		resources necessary to address global immunization needs. 

•		Work with partners to ensure adequate funding for polio eradication,
		measles mortality reduction and regional elimination, the Hib Initiative,
		hepatitis B control, and other initiatives.

•		W	ith partners, advocate for creation of stockpiles/strategic reserves
		of vaccines to maintain uninterrupted supply, for emergency response
		to outbreaks, and for special purposes (e.g., global OPV stockpile).

•		Collaborate with partners to advocate for increasing use of vaccines in
		adults (e.g., vaccination of health care workers, pneumococcal and 					influenza vaccination, Td and Tdap boosters, HPV).